ALX ONCOLOGY HOLDINGS INC (ALXO) Form 8-K — Jun 26, 2026

$ALXOForm 8-KItems 1.01, 1.02, 2.03, 9.01Filed Jun 26, 2026, 4:02 PM ET0001193125-26-285425Original filing

ALX Oncology entered into a secured multi-tranche term loan agreement with HSBC Ventures USA Inc. for an aggregate principal amount of up to $50 million. The company borrowed $10 million at closing, using the proceeds to refinance its existing loan agreement with Oxford Finance and Silicon Valley Bank and to pay closing fees. The facility includes an additional $20 million available to draw through June 30, 2028, and a further $10 million contingent upon achieving positive data milestones for the Phase 2 ASPEN-09 study of Evorpacept and the Phase 1 study of ALX2004.

Key figures

Debt Amount: $50,000,000
Interest Rate: Prime Rate or 6.0%
Maturity Date: June 1, 2030
Final Payment Fee: 2.0%
Initial Borrowing: $10,000,000
Milestone Tranche: $10,000,000
Prepayment Fee Year1: 2.0%
Prepayment Fee Year2: 1.0%
Additional Available: $20,000,000
Discretionary Tranche: $10,000,000

Price after filing

1 day: 0.0%7 days: +15.6%30 days: +12.8%

Close on the filing date to close N calendar days later (from $1.79). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.